

CHECKLIST OF RESPONSIBILITIES FOR SCIENTIFIC EDITORS

Manuscript page number (Without Figures): 16 Rate: 6.2 CNY per page

Editing Fee: <u>99.2 CNY</u>

Figure count: ______Figure handling time: ______min Rate: 1 CNY per min

Editing Fee: <u>CNY</u>

XML and PDF converting time: 44 min Rate: 1 CNY per min

Editing Fee: <u>44</u> CNY

Manuscript word count: 4050

Total Editing Fee: 143.2 CNY

Scientific Editor: Jia-Ru Fan

Date of signature: _____(month/day/year)

| | | Comments |
|----------|---|----------|
| Item No. | Specific items for verification | Yes=[Y] |
| | | No= [N] |
| | General Information of the Manuscript | |
| | Name of journal: World Journal of Gastroenterology | |
| | Manuscript NO.: 77136 | |
| | Column: Letter to the Editor | |
| 1 | Title: Endoluminal vacuum-assisted therapy as a treatment for | [2] |
| 1 | anastomotic leakage in colorectal surgery | [Y] |
| | Authors: Maria Michela Chiarello, Valentina Bianchi, Pietro | |
| | Fransvea and Giuseppe Brisinda | |
| | Reviewer code: 04970307, 04164271, and 06196661 | |
| | First decision: 2022-05-11 20:37 | |
| 2 | Editorial Office's Comments | [Y] |



| | Science Editor:1. The title of the article you are | |
|---|---|-----|
| | commenting on is not allowed in the title. Please revise2. | |
| | Your manuscript has been checked by CrossCheck. Please read the | |
| | attached CrossCheck report for details. Similar sentences with other | |
| | articles (highlighted in the CrossCheck Report), please rephrase | |
| | these sentences. Our editorial policy states the overall similarity | |
| | should be less than 30%, the overlapped section should be less than | |
| | 5% in single papers, including author's own work. Please modify on | |
| | the basis of the attached manuscript. | |
| | Company Editor-in-Chief: I have reviewed the Peer-Review | |
| | Report, full text of the manuscript, and the relevant ethics | |
| | documents, all of which have met the basic publishing requirements | |
| | of the World Journal of Gastroenterology, and the manuscript is | |
| | conditionally accepted. I have sent the manuscript to the author(s) | |
| | for its revision according to the Peer-Review Report, Editorial | |
| | Office's comments and the Criteria for Manuscript Revision by | |
| | Authors. | |
| 3 | The fixed headings are copied. | [Y] |
| | The title concisely summarizes the main topic of the study and is | |
| | not too long (no more than 18 words). Words such as 'exploration', | |
| 4 | 'research', 'analysis', 'observation', and 'investigation' are avoided. | [Y] |
| | The title does not start with 'The' and does not include any Arabic | |
| | numbers or uncommon abbreviations. | |
| 5 | A short running title is provided (no more than 6 words). | [Y] |
| | The authors' full family (sur)names and full/abbreviated first | |
| 6 | names are listed on the title page and are consistent with those | [Y] |
| | listed in the signed BPG Copyright License Agreement form. | |
| | | |



| 7 | The 'Author contributions' passage describes the specific contribution(s) made by each author. The author's names are listed in the following format: full family (sur)name followed by abbreviated first and middles names. <i>e.g.</i> , "Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research study; Wang CL, Zou CC, Hong F and Wu XM performed the research; Xue JZ and Lu JR contributed new reagents and analytic tools; Wang CL, Liang L and Fu JF analyzed the data; and Wang CL, Liang L and Fu JF wrote the manuscript. All authors have read and approve the final manuscript." | [Y] |
|----|---|-----|
| 8 | The 'Supported by' statement describes the source(s) of financial support and includes the corresponding identification number(s) and program ID(s) if available, and contains no spelling errors. | [N] |
| 9 | The 'Corresponding author' passage provides the corresponding author's full first and family (sur)names, abbreviated title (<i>e.g.</i> , MD, PhD), affiliated institute's name and complete postal address (including zip code) and e-mail (written in all lowercase), and contains no spelling errors. | [Y] |
| 10 | The Manuscript Tracking information (<i>i.e.</i> , Received, Peer review started, First decision, Revised, Accepted, Article in press, and Published online) are provided along with the corresponding editor and date for each item, and contain no spelling errors. | [Y] |
| 11 | The Abstract section is formatted according to the article-specific style (structured <i>vs</i> unstructured) and word count thresholds, as follows: <u>Commentary, Frontier, Diagnostic Advances, Medical Ethics,</u> <u>Minireview, Review, Therapeutics Advances, and Topic Highlight</u> : Non-structured abstract that is no less than 200 words. <u>Field of Vision, Case Report and Letter to the Editor</u> : | [Y] |



| | | 1 |
|--------------|---|-----|
| N | Non-structured abstract that is no less than 150 words. | |
| <u>R</u> | Research articles: Structured abstract with subsections for AIM (no | |
| n | nore than 20 words); METHODS (no less than 80 words); RESULTS | |
| (1 | no less than 120 words); and CONCLUSION (no more than 26 | |
| W | vords). | |
| Т | The 'Key words' list provides 5-10 keywords that reflect the main | |
| 12 co | ontent of the study. The first letter of each keyword is capitalized, | [Y] |
| a | nd each keyword is separated by a semicolon. | |
| Т | The "citation" contains authors' names and manuscript title. The | |
| n | name of the first author should be typed in bold letters; the family | |
| (5 | sur) name of all authors should be typed with the first letter | |
| Са | apitalized, followed by their abbreviated first and middle initials. | |
| 13 F | For example, an article by Jae Moon Yoon, Ki Young Son, Chun Sick | [Y] |
| E | Eom, Daniel Durrance, Sang Min Park will be written as Yoon JM, | |
| S | Son KY, Eom CS, Durrance D, Park SM. Pre-existing diabetes | |
| m | nellitus increases the risk of gastric cancer: A meta-analysis. World J | |
| G | Gastroenterol 2019; In press | |
| Т | The 'Core tip' provides a summary (less than 100 words) of the | |
| st | tudy that outlines the most innovative and important arguments | D/1 |
| 14 at | nd core contents of the paper and will serve to effectively attract | [Y] |
| re | eaders. | |
| Т | The 'INTRODUCTION' section clearly describes the relevant | |
| b | packground information for the study. Only the most relevant and | |
| СТ | urrent (within the past 5 years) literature is cited, with the | |
| e | exception of rare instances of seminal literature citations. All | |
| 15 te | echnical terms and/or abbreviations are explained and/or defined, | [N] |
| W | vith the full name of abbreviations given upon first appearance in | |
| tł | he text and the abbreviation presented in parentheses [i.e., | |
| " | computed tomography (CT)"]. First-person pronouns (e.g., 'I', | |
| 'v | we') are used appropriately to clearly indicate the work performed | |



| | has the souther (a) TATI and success of any interview of the | |
|----|---|--------|
| | by the author(s). When weaknesses of previous studies are | |
| | described in the text to highlight the innovations related to the | |
| | current study, the information is presented carefully. | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | The 'MATERIALS AND METHODS' section clearly and accurately | |
| 10 | describes all materials and methods used to obtain the data | [3, 7] |
| 16 | presented in the article and is adequate for a reader to repeat the | [N] |
| | study. | |
| | The 'RESULTS' section concisely describes the observational and | |
| | experimental results. Representative data and data that have | |
| | scientific significance are emphasized. Data is presented in either | |
| 17 | the text, a table or figure (<i>i.e.</i> , chart, diagram, graph or image), but is | [N] |
| | not repeated among each. Information presented in the tables and | |
| | figures clearly describes the trends, meaning, and inferences. | |
| | Results described in textual form are accurate, concise and clear. | |
| | Statistical symbols are accurate. Statistical significance is expressed | |
| | as ${}^{a}P < 0.05$, ${}^{b}P < 0.01$ ($P > 0.05$ usually does not need to be denoted). | |
| 18 | If there are other series of <i>P</i> values, $^{c}P < 0.05$ and $^{d}P < 0.01$ are used, | [N] |
| | and a third series of <i>P</i> values is expressed as ${}^{e}P < 0.05$ and ${}^{f}P < 0.01$. | [+ ·] |
| | Statistical data is expressed as mean \pm SD or mean \pm SE. | |
| | Statistical data is expressed as mean I SD of mean I SE. | |



| 19 | The 'DISCUSSION' section (1) describes the main purpose and | |
|----|--|------|
| | hypothesis of the study; (2) summarizes the most important results; | |
| | (3) illustrates and explains the results (but does not simply repeat | |
| | the data) and draws conclusions or inferences based on the results; | [N] |
| | (4) points out the limitations of the study and their impact on the | |
| | results, as well as proposes further advice on future research | |
| | topic(s) or direction(s); and (5) describes the theoretical significance | |
| | and practical value of the findings. | |
| | The 'ACKNOWLEDGEMENTS' section expresses gratitude to any | |
| | individuals or organizations for technical support (i.e., providing | |
| 20 | instrumentation, equipment or experimental materials, and/or | D TI |
| 20 | assistance in experimental work), non-technical services (i.e., useful | [N] |
| | inspiration, suggestions, guidance, or review), and/or any other | |
| | auxiliary work. | |
| 21 | The 'ARTICLE HIGHLIGHTS' section provides comments for | [N] |
| 21 | original articles in accordance with the specified format. | |
| | The 'REFERENCES' section lists the references in the Vancouver | |
| | style. This style uses Arabic numeral in-text citations based on the | |
| | order of the first appearance of a source in the text. For citations | |
| | where the author's name is indicated in the text, a superscript | |
| | number should be placed following the name (<i>i.e.,</i> "Pang <i>et al</i> "). For | [Y] |
| | citations where no author is indicated, a superscript number should | |
| 22 | be placed at the end of the sentence. Respective examples are: " $Ma^{[1]}$ | |
| | reported", "Pan et al ^[2-5] indicated"; "PCR has a high | |
| | sensitivity ^[6,9] ." No superscript numbers are used when the | |
| | reference number is described in the text; for example, "The | |
| | experimental method used has been described in reference [8]." The | |
| | style of reference citations in tables is the same as that in the text | |
| | (<i>e.g.,</i> Pan <i>et al</i> ^[2-5] , please see reference [8]). | |
| | | |



| 23 | Journal references have been verified to ensure that there are no | |
|----|---|------|
| | duplicate references and that the PMID numbers are correct. For | |
| | references not yet included in PubMed: the name of Chinese | |
| | journals is spelled out using Chinese Pinyin, with the first letter of | [1/] |
| | each word capitalized (e.g., Shijie Huaren Xiaohua Zazhi); the name of | [Y] |
| | journals in other languages are listed according to indexing | |
| | information retrieved from Google. Book references are presented | |
| | with all the information relevant to the electronic version. | |
| | The number of cited references is appropriate for the article type, as | |
| | follows: | |
| 24 | <u>Commentary:</u> no less than 50; | D.O. |
| 24 | <u>Review:</u> no less than 100; | [Y] |
| | <u>Article:</u> no less than 30/26; | |
| | Case Report and Letter to the Editor: no less than 1. | |
| | The ethics-related statements are provided in accordance with the | |
| 25 | manuscript type (e.g., Manuscript NoInstitutional review board | [N] |
| | statement, Manuscript NoAnimal care and use statement, etc.). | |
| | The names of the peer reviewers and the scientific editor are present | |
| 26 | at the end of the paper (e.g., P-Reviewer: Hugot D S-Editor: Wang | [Y] |
| | JL). | |
| | The order and numerical labeling of tables and figures is consistent | |
| | with their appearance and presentation in the text. Symbols in | |
| 27 | tables (e.g., +, -, ×, \div , *) correctly correspond to the definitions in the | |
| | footnotes. Only one legend is provided for each multi-panel figure | [NI] |
| 21 | consisting of color graphs, black and white graphs, or line graphs | [N] |
| | that depicts data of the same theme. For example: Figure 1 | |
| | Pathological changes in atrophic gastritis tissue before and after | |
| | treatment. A:; B:; C:; D:; E:; F: | |
| 28 | Split pictures include flow charts, line graphs, histograms, and | [N] |
| 20 | graphs including text. Unsplit pictures include meta-analysis | |
| | | |



| | diagrams, PCR amplification curves, and survival curves. | |
|----|--|-----|
| 29 | The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments. | [Y] |
| 30 | The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript. | [Y] |
| 31 | The revised manuscript is provided (file name: ManuscriptNoReview; e.g., 870- Review).The letter of peer-reviewers' comments is provided (file name:Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)).The response letter is provided (file name: ManuscriptNoAnswering reviewers; e.g., 870-Answering reviewers). | [Y] |
| 32 | The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript NoInstitutional animal care and use committee statement), and (7) Signed informed consent form(s) or document(s) (file name: | [Y] |
| 33 | All authors signed the BPG Copyright license agreement form (file name: Manuscript NoCopyright license agreement; <i>e.g.</i> , 870-Copyright license agreement). | [Y] |
| 34 | The language certificate provided by authors who are non-native speakers of English meets the BPG requirements (file name: | [Y] |



| | the authors' copyright) has been performed for the manuscript <i>via</i> | |
|--|--|--|
| | | |
| | the website: http://www.ithenticate.com/. The results document | |
| | contains the following information for the manuscript: "Name of | |
| 37 | journal", "Manuscript No.", "Columns", "Title" and "Author list". | [Y] |
| | The Figure of the CrossCheck results is saved in JPEG format (.jpg) at | |
| | 1440 × 680 pixel resolution. The PDF of the CrossCheck results has | |
| | been saved under the file name: manuscript No CrossCheck report | |
| | (e.g., 870-CrossCheck report). The Google searches have also been | |
| | performed to further ensure publication of original content. | |
| | The text of the manuscript is typed in Book Antiqua font, 12 pt, with | |
| 38 | 1.5 line spacing. | [Y] |
| | The primary responsibilities of our scientific editors include carefull | y checking the |
| | | _ |
| Responsibilities of scientific editors | entire manuscript and all accompanying materials for: (1) error | 1 0 |
| | grammar, punctuation and wording; (2) suitability of tables, figures, figure data and | |
| | legends; (3) accurate and appropriate presentation of symbols (e.g. +, -, ×, \div , %, *) in | |
| | tables and figures; and (4) complete and comprehensive revision of t | he manuscript |
| | | · ···································· |
| | according to the reviewers' comments. | |



| | Manuscript reception and registration-Initial review by scientific editor-Peer | |
|-------------|--|--|
| | review \rightarrow End of peer review \rightarrow First round of meeting evaluation \rightarrow To be | |
| | accepted \rightarrow Revision by the author(s) \rightarrow Second round of meeting evaluation \rightarrow To be | |
| | accepted/revised/rejected \rightarrow Final review by the Editor-in-Chief (final quality | |
| Publication | control for academic content and language quality)→Final acceptance and charging | |
| process | of publication fee \rightarrow Language editing \rightarrow Production \rightarrow Proofreading by scientific | |
| | editor \rightarrow Proofreading by deputy editor \rightarrow Final review by Editor-in-Chief \rightarrow Release | |
| | of online open-access papers in electronic form on the BPG website \rightarrow Release of | |
| | online papers on PubMed Central→Delivery of high-quality PDF reprints to the | |
| | author(s) \rightarrow End of the publication process. | |